CL2013000200A1 - Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos. - Google Patents

Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos.

Info

Publication number
CL2013000200A1
CL2013000200A1 CL2013000200A CL2013000200A CL2013000200A1 CL 2013000200 A1 CL2013000200 A1 CL 2013000200A1 CL 2013000200 A CL2013000200 A CL 2013000200A CL 2013000200 A CL2013000200 A CL 2013000200A CL 2013000200 A1 CL2013000200 A1 CL 2013000200A1
Authority
CL
Chile
Prior art keywords
active form
antibody
enhanced active
human insulin
metabolic disorders
Prior art date
Application number
CL2013000200A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of CL2013000200A1 publication Critical patent/CL2013000200A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013000200A 2010-07-21 2013-01-21 Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos. CL2013000200A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами

Publications (1)

Publication Number Publication Date
CL2013000200A1 true CL2013000200A1 (es) 2015-01-23

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000200A CL2013000200A1 (es) 2010-07-21 2013-01-21 Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos.

Country Status (29)

Country Link
US (1) US8617555B2 (es)
EP (2) EP3693018A1 (es)
JP (2) JP2013533268A (es)
KR (2) KR20180127515A (es)
CN (1) CN103118707A (es)
AR (1) AR082312A1 (es)
AU (1) AU2011281240B2 (es)
BR (1) BR112013001299A2 (es)
CA (1) CA2805961A1 (es)
CL (1) CL2013000200A1 (es)
CZ (1) CZ2013124A3 (es)
DE (1) DE112011102396T5 (es)
DK (1) DK201370089A (es)
EA (1) EA029847B1 (es)
EE (1) EE05761B1 (es)
ES (1) ES2445846R1 (es)
FI (1) FI20135152L (es)
FR (1) FR2962913A1 (es)
GB (2) GB2552405B (es)
IT (1) ITTO20110627A1 (es)
LT (1) LT5980B (es)
MX (1) MX2013000804A (es)
MY (1) MY160979A (es)
NO (1) NO20130265A1 (es)
NZ (1) NZ606964A (es)
PE (1) PE20130815A1 (es)
SE (1) SE1350212A1 (es)
SG (1) SG187578A1 (es)
WO (1) WO2012010966A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
SE1350179A1 (sv) 2010-07-15 2013-04-12 Oleg Iliich Epshtein Farmaceutiska sammansättningar och behandlingsförfaranden
AU2011287288A1 (en) 2010-07-15 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593140A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
JP2013535444A (ja) 2010-07-21 2013-09-12 イリイチ・エプシテイン オレグ 注意欠陥多動性障害を治療する方法
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
US20130045237A1 (en) * 2010-08-06 2013-02-21 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
AU2003262804A1 (en) * 2002-08-22 2004-03-11 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
WO2005067928A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
SE1350179A1 (sv) * 2010-07-15 2013-04-12 Oleg Iliich Epshtein Farmaceutiska sammansättningar och behandlingsförfaranden
EP2593140A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
AU2011287288A1 (en) * 2010-07-15 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
KR20130102542A (ko) * 2010-07-21 2013-09-17 올레그 일리치 엡쉬테인 현기증, 동요병 및 증식형-혈관 이긴장증 치료용 제약학적 복합 조성물 및 치료 방법들
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria

Also Published As

Publication number Publication date
MY160979A (en) 2017-03-31
GB201707872D0 (en) 2017-06-28
ES2445846A2 (es) 2014-03-05
MX2013000804A (es) 2013-10-28
SG187578A1 (en) 2013-03-28
PE20130815A1 (es) 2013-07-18
AR082312A1 (es) 2012-11-28
EP2595658A2 (en) 2013-05-29
LT5980B (lt) 2013-12-27
CN103118707A (zh) 2013-05-22
DK201370089A (en) 2013-02-19
GB2552405A (en) 2018-01-24
NO20130265A1 (no) 2013-04-18
ES2445846R1 (es) 2015-01-02
FR2962913A1 (fr) 2012-01-27
KR20180127515A (ko) 2018-11-28
WO2012010966A2 (en) 2012-01-26
WO2012010966A3 (en) 2012-03-29
LT2013018A (lt) 2013-10-25
NZ606964A (en) 2015-08-28
EP3693018A1 (en) 2020-08-12
GB2496799A (en) 2013-05-22
EE201300007A (et) 2013-08-15
US8617555B2 (en) 2013-12-31
GB2496799B (en) 2017-11-22
EE05761B1 (et) 2016-03-15
BR112013001299A2 (pt) 2017-11-21
AU2011281240B2 (en) 2016-07-07
CZ2013124A3 (cs) 2013-06-12
JP2013533268A (ja) 2013-08-22
EA029847B1 (ru) 2018-05-31
EA201300124A1 (ru) 2013-12-30
GB2552405B (en) 2018-05-30
GB201302924D0 (en) 2013-04-03
ITTO20110627A1 (it) 2012-01-22
SE1350212A1 (sv) 2013-04-22
KR20130103486A (ko) 2013-09-23
DE112011102396T5 (de) 2013-05-02
US20130064824A1 (en) 2013-03-14
FI20135152L (fi) 2013-02-21
AU2011281240A1 (en) 2013-03-07
CA2805961A1 (en) 2012-01-26
JP2016222684A (ja) 2016-12-28

Similar Documents

Publication Publication Date Title
CL2013000200A1 (es) Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos.
BR112013033803A2 (pt) formulação integrada com microagulha, e, método para administrar uma substância
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
BR112013002167A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
BR112013012782A2 (pt) anticorpos humanos para o receptor de glucagon
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI0917204A2 (pt) variantes estruturais de anticorpos para melhores características terapêuticas
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
BR112014015042A8 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
BR112012026686A2 (pt) fórmulas melhoradas para dispositivos médicos revestidos com droga
BR112013017669A2 (pt) di-hidrofuranos fundidos como moduladores de gpr119 para o tratamento de diabetes, obesidade e doenças relacionadas
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2013000237A1 (es) Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
ES1076496Y (es) Conjunto para formación de cápsulas rellenables para preparación de infusiones.
ES2641042T8 (es) Procedimiento para la fabricación de un fármaco proteínico
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2013003377A1 (es) Conjugado polipeptídico que comprende un componente polipeptídico covalentemente unido a una fracción que aumenta la duración; composición farmacéutica que comprende un conjugado polipeptídico; método para tratar una enfermedad o desorden en un sujeto.